GMGayathri Pramil Menon

Gayathri Pramil Menon

*This is an algorithmically generated author record based on publicly available information.

Gayathri Pramil Menon has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exosomal MicroRNAs in Pancreatic Ductal Adenocarcinoma: Mechanism of Proliferation, Diagnosis, Prognosis, and Treatment

    by Anusree Chakraborty, Anirudh, Pedro Vega Guillen, Thy Dinh Van Le, Gayathri Pramil Menon

    Pancreatic cancer remains one of the deadliest malignancies worldwide, largely because it is often asymptomatic in its early stages and therefore diagnosed late, when curative treatment options are limited. In the United States, it accounts for approximately 3% of all cancers and about 8% of all cancer‐related deaths. Pancreatic ductal adenocarcinoma is the most common histologic subtype and continues to have a very poor prognosis, underscoring the urgent need for improved early detection strategies. Current diagnostic approaches, including magnetic resonance imaging (MRI) and contrast‐enhanced computed tomography (CT), are useful mainly in high‐risk populations, whereas emerging combinations such as ultrasound with MRI may broaden screening potential. In parallel, growing interest has focused on molecular diagnostics, particularly microRNAs (miRNAs), which regulate gene expression posttranscriptionally and have been implicated in pancreatic cancer biology. Although miRNA‐based approaches are promising for early diagnosis, prognosis, and treatment response assessment, most evidence remains derived from preclinical studies or small clinical cohorts and requires further validation before routine clinical use. This review examines the current evidence on the roles of miRNAs in the diagnosis, prognosis, and treatment of pancreatic cancer.

  • Open Access

    Gut Microbiota and Gastric Cancer: The Immunoregulatory Mechanism and the Preventive Role of Microbiota‐Derived Short‐Chain Fatty Acids

    by Anusree Chakraborty, Pedro Vega Guillen, Om Prakash Bhatta, Ummul Asfeen, Anirudh, Gayathri Pramil Menon, Alsalt Al-Busaidi, Priyanka Sahajwani, Rohit Chandra Dey, Seelamonthula Vaibhav Sai

    Gastric cancer is still a major worldwide health problem, and its etiology is attributed to several factors, including the composition of the gut microbiota and its immunomodulatory functions. The present review discusses the complex interrelationship between the gut microbiota metabolites, especially short‐chain fatty acids (SCFAs) and the onset of gastric cancer. Dysbiosis of the gut microbiota, reduced diversity of microbial species, and increased relative abundance of certain bacterial taxa have been found to contribute to the progression of gastric cancer and its treatment. For instance, Helicobacter pylori is still considered a well‐recognized cause; nevertheless, other bacteria, such as Enterobacteriaceae and Prevotella , have emerged as putative gastric cancer causative agents in recent investigations. In addition, SCFAs, particularly butyrate, produced in the gut are known to modulate immune functions by enhancing the cytotoxic activity of CD8+ T cells and preventing gastric cancer, possibly via the GPR109A receptor. Although research on the cause–effect relationship between microbiota and gastric cancer is an emerging field, available data from human and animal studies suggest that the manipulation of the gut microbiota—through probiotics, diet, or specific treatments—may be useful in preventing and managing gastric cancer. This review discusses the role of gut microbiota and SCFAs in the diagnosis and therapy of gastric cancer, with a focus on their effective application in gastric cancer treatment.